155 related articles for article (PubMed ID: 32850435)
1. Expression of PD-L1 on Monocytes Is a Novel Predictor of Prognosis in Natural Killer/T-Cell Lymphoma.
Zhang XW; Bi XW; Liu PP; Liu ZL; Nie M; Yang H; Lei DX; Xia Y; Jiang WQ; Zeng WA
Front Oncol; 2020; 10():1360. PubMed ID: 32850435
[No Abstract] [Full Text] [Related]
2. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate.
Zhou Z; Chen X; Li Z; Wang X; Zhang M
Sci Rep; 2021 May; 11(1):11220. PubMed ID: 34045609
[TBL] [Abstract][Full Text] [Related]
4. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
[TBL] [Abstract][Full Text] [Related]
5. SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential.
Xiong J; Wang N; Zhong HJ; Cui BW; Cheng S; Sun R; Chen JY; Xu PP; Cai G; Wang L; Sun XJ; Huang JY; Zhao WL
EBioMedicine; 2021 Oct; 72():103614. PubMed ID: 34628354
[TBL] [Abstract][Full Text] [Related]
6. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.
Jo JC; Kim M; Choi Y; Kim HJ; Kim JE; Chae SW; Kim H; Cha HJ
Ann Hematol; 2017 Jan; 96(1):25-31. PubMed ID: 27696202
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
[TBL] [Abstract][Full Text] [Related]
8. Platelet-derived growth factor receptor alpha (PDGFRα) is overexpressed in NK/T-cell lymphoma and mediates cell survival.
Lu L; Fu X; Li Z; Qiu Y; Li W; Zhou Z; Xue W; Wang Y; Jin M; Zhang M
Biochem Biophys Res Commun; 2018 Oct; 504(2):525-531. PubMed ID: 30201265
[TBL] [Abstract][Full Text] [Related]
9. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
[TBL] [Abstract][Full Text] [Related]
10. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
11. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
12. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
[TBL] [Abstract][Full Text] [Related]
14. Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma.
Li Y; Fei Y; Liu L; Song Z; Meng X; Qiu L; Li L; Qian Z; Zhou S; Ren X; Bi C; Meng B; Zhang H; Wang X; Fu K
J Cancer; 2021; 12(20):6126-6134. PubMed ID: 34539885
[No Abstract] [Full Text] [Related]
15. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of programmed death-ligand 1 and programmed death-1 on antigen-presenting cells as a predictor of organ dysfunction and mortality during early sepsis: a prospective cohort study.
Li JB; Xie MR; Duan ML; Yu YN; Hang CC; Tang ZR; Li CS
World J Emerg Med; 2023; 14(3):179-185. PubMed ID: 37152526
[TBL] [Abstract][Full Text] [Related]
19. Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma.
Xiong J; Cheng S; Gao X; Yu SH; Dai YT; Huang XY; Zhong HJ; Wang CF; Yi HM; Zhang H; Cao WG; Li R; Tang W; Zhao Y; Xu PP; Wang L; Zhao WL
Signal Transduct Target Ther; 2024 Mar; 9(1):62. PubMed ID: 38448403
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
